G01N2800/2864

TREATMENT OF CIRCADIAN RHYTHM DISORDERS

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

METHOD FOR DIAGNOSING OR MONITORING CONDITIONS CHARACTERIZED BY ABNORMAL TEMPORAL VARIATIONS AND METHOD OF NORMALIZING EPIGENETIC DATA TO COMPENSATE FOR TEMPORAL VARIATIONS

Methods for diagnosing or monitoring a condition, disorder or disease associated with circadian, diurnal or other temporal rhythms by detecting circa-miRNAs and circa-microbiomes associated with said condition, disorder or disease. Methods for correcting or normalizing sequence data to correct for diurnal or circadian fluctuations in quantities of circa-miRNAs and/or circa-microbiomes by adjusting or normalizing values based on the time of day when a saliva sample containing these RNAs was collected.

TREATMENT OF CIRCADIAN RHYTHM DISORDERS

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Method and Compound for Modifying Circadian Clock
20200009134 · 2020-01-09 ·

Circadian rhythm is modulated by administering a circadian rhythm phase-shifting hPER2 phosphorylating kinase inhibitor.

Treatment of circadian rhythm disorders

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Treatment of circadian rhythm disorders

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Basal Ganglia-On-Chip For Screening Therapeutic Agents For Brain And Nervous System Diseases

The present disclosure provides a basal ganglia-on-a-chip for screening therapeutic agents for brain and nervous system diseases and a method for fabricating the same. The present invention provides a method for screening therapeutic agents for dopamine-dependent brain and nervous system diseases by using a basal ganglia-on-a-chip. When the basal ganglia-on-a-chip of the present invention is used in the effect evaluation of therapeutic agents for brain and nervous system diseases, the effect evaluation of therapeutic candidate substances can be economically and promptly carried out compared with an existing technique.

Basal ganglia-on-chip for screening therapeutic agents for brain and nervous system diseases

The present disclosure provides a basal ganglia-on-a-chip for screening therapeutic agents for brain and nervous system diseases and a method for fabricating the same. The present invention provides a method for screening therapeutic agents for dopamine-dependent brain and nervous system diseases by using a basal ganglia-on-a-chip. When the basal ganglia-on-a-chip of the present invention is used in the effect evaluation of therapeutic agents for brain and nervous system diseases, the effect evaluation of therapeutic candidate substances can be economically and promptly carried out compared with an existing technique.

DETERMINING MELATONIN LEVEL IN A BIOLOGICAL SAMPLE

The disclosure pertains to determining a melatonin level in a biological sample of a subject with a determination system. The determination system comprises a melatonin analyzer, a temperature sensor, and a controller. The method comprises providing a first biological sample from the subject to the melatonin analyzer; generating one or more output signals conveying information related to a temperature of the analyzer; controlling the temperature of the analyzer based on the output signals to be within a pre-determined temperature range, such that responsive to the temperature of the analyzer being outside the pre-determined temperature range, the controlling comprises cooling and/or heating the analyzer to bring and maintain the temperature within the pre-determined temperature range; and responsive to the temperature of the analyzer being within the pre-determined temperature range, facilitating determination of a melatonin level of the first biological sample with the analyzer.

TREATMENT OF CIRCADIAN RHYTHM DISORDERS

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.